The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 329:361-362 July 29, 1993 Number 5
NextNext

Hodgkin's Disease

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
by DeVita, V. T.
To the Editor: In their review of drug therapy for Hodgkin's disease (Feb. 25 issue),1 DeVita and Hubbard cite two trials conducted to compare chemotherapy alone with radiotherapy alone as treatment for stage I or II Hodgkin's disease2,3. They stated that both trials demonstrated that "combination therapy was as effective as radiotherapy." The overall survival in the study by Biti et al.,2 with a median follow-up of eight years, however, was significantly higher among patients treated with radiotherapy than among those treated with chemotherapy (93 percent vs. 56 percent, P<0.001). Furthermore, the survival among patients who relapsed after initial . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.